Myelodysplastic Syndrome (MDS)
Showing NaN - NaN of 6
Myelodysplastic Syndrome (MDS) Trial in Worldwide (Venetoclax, Azacitidine, Placebo)
Active, not recruiting
- Myelodysplastic Syndrome (MDS)
- Venetoclax
- +2 more
-
Fullerton, California
- +219 more
Aug 24, 2022
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Worldwide (Lemzoparlimab, Azacitidine, Venetoclax)
Recruiting
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Lemzoparlimab
- +2 more
-
Birmingham, Alabama
- +35 more
Aug 19, 2022
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Chicago (Haplo-Cord Transplant, Matched Unrelated Donor
Terminated
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Haplo-Cord Transplant
- Matched Unrelated Donor Transplant
-
Chicago, IllinoisUniversity of Chicago Cancer Center
Feb 22, 2021
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) Trial in United States
Completed
- Acute Myeloid Leukemia (AML)
- +3 more
- Selinexor
- +3 more
-
Phoenix, Arizona
- +5 more
Mar 25, 2020
Allogeneic HCT Compared to Chemotherapy in Older AML Patients
Completed
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
-
Stanford, California
- +11 more
Nov 12, 2019
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS) Trial in Chicago, Ann Arbor, Fairfax
Unknown status
- Acute Myelogenous Leukemia (AML)
- +3 more
- Sargramostim
- +2 more
-
Chicago, Illinois
- +2 more
Apr 18, 2016